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Abstract
Eosinophil granulocytes reside in respiratory mucosa including lungs, in the gastro-intestinal tract, and in
lymphocyte associated organs, the thymus, lymph nodes and the spleen. In parasitic infections, atopic diseases
such as atopic dermatitis and asthma, the numbers of the circulating eosinophils are frequently elevated. In
conditions such as Hypereosinophilic Syndrome (HES) circulating eosinophil levels are even further raised.
Although, eosinophils were identified more than hundred years ago, their roles in homeostasis and in disease still
remain unclear. The most prominent feature of the eosinophils are their large secondary granules, each containing
four basic proteins, the best known being the eosinophil cationic protein (ECP). This protein has been developed
as a marker for eosinophilic disease and quantified in biological fluids including serum, bronchoalveolar lavage and
nasal secretions. Elevated ECP levels are found in T helper lymphocyte type 2 (atopic) diseases such as allergic
asthma and allergic rhinitis but also occasionally in other diseases such as bacterial sinusitis. ECP is a ribonuclease
which has been attributed with cytotoxic, neurotoxic, fibrosis promoting and immune-regulatory functions. ECP
regulates mucosal and immune cells and may directly act against helminth, bacterial and viral infections. The levels
of ECP measured in disease in combination with the catalogue of known functions of the protein and its
polymorphisms presented here will build a foundation for further speculations of the role of ECP, and ultimately
the role of the eosinophil.
Discovery of the eosinophils
Eosinophils were discovered in the blood of humans,
frogs, dogs and rabbits in 1879 by Dr. Paul Ehrlich [1].
At that time, the German chemical industry was flour-
ishing and Ehrlich took advantage of newly developed
synthetic dyes to develop various histological staining
techniques. The coal tar derived, acidic and bromide
containing dye eosin identified blood cells containing
bright red “alpha-granules” and the cells were named
eosinophilic granulocytes. Due to the acidity of the
staining solution Ehrlich could not at the time say with
certainty that the eosinophilic granules contained pro-
tein, though he speculated that if present, protein might
be denatured by the low pH of the dye [1]. Subsequently
it was shown that eosin binds highly basic proteins
which constitute the granules of these cells. These
charged proteins are contained in on average twenty
large granules dispersed throughout the cytoplasm of
each cell, which the eosin stain awards the characteristic
red spotted appearance that discriminates eosinophils
from other leukocytes [2]. More than a century later the
physiological roles of these granular proteins have yet to
be fully identified.
In eosinophil granules pH is maintained at 5.1 by an
ATPase [3] where the basic proteins are packed forming
crystals [2]. The main content of these granules are four
proteins, the major basic protein (MBP) present in their
cores, surrounded by a matrix built up of eosinophil
peroxidise (EPO), the eosinophil protein X/eosinophil
derived neurotoxin (EPX/EDN) and ECP. Vesicotubular
structures within the granules direct a differential
release of these proteins [4]. The granule proteins were
all discovered and characterised about one hundred
years after the discovery of the eosinophils [5-8]. ECP is
the best know of the proteins, assessed and used exten-
sively as a marker in asthma and other inflammatory
diseases. ECP has been scrutinized in a number of func-
tional studies. The aim of this article is to review some
of the findings of ECP quantifications in various diseases
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and set those in context of the experiments that have
functionally analysed the protein. The findings will be
used as guidance in a speculation of the biological role
of eosinophil.
ECP is mainly produced during the terminal
expansion of the eosinophils in the bone marrow
Eosinophil progenitors (EoP’s) in the bone marrow are
the first cell identified exclusively of the eosinophil
lineages. These EoP’s express the cell surface markers
IL-5R+ CD34+ CD38+ IL-3R+ CD45RA-, haematopoietic
lineage associated transcription factor GATA-1, ECP
mRNA transcripts and have visual characteristics of
early eosinophilic blast cell [9,10]. Most of the granule
protein production takes place as EoP’s undergo the
final stages of maturation [11,12]. ECP is synthesised,
transported and stored in the mature secondary granules
at such a high rate as that when the eosinophils are
ready to leave the bone marrow, they contain 13.5 μg
ECP/106 cells [13] (Figure 1B). Eosinophils are the
major ECP producing cell while monocytes and myelo-
monocytic cell lines produce minute amounts in com-
parison [14]. Activated [15] but not resting neutrophils
also produce some ECP and have the ability to take up
further ECP from the surrounding environment storing
it in their azurophil granules [16,17]. In the myelo-eosi-
nophilic cell line HL-60 clone 15, ECP production is
dependent on a nuclear factor of activated T-cells
(NFAT)-1 binding site in the intron of the ECP gene
(denoted RNASE3) [18]. The RNASE3 gene was formed
by gene duplication of an ancestral gene about 50
million years ago, the other duplication gene product
being the eosinophil granule protein EPX/EDN gene
(RNASE2). ECP and EPX/EDN are two ribonucleases
with such a high degree of homology that they are
unique to humans and primates and not found in other
species. After this gene duplication however, ECP lost
part of its ribonuclease activity, but acquired cytotoxic
activity, whereas EDN/EPX remained a potent ribonu-
clease [19].
ECP a cytotoxic ribonuclease
ECP has homology to pancreatic ribonuclease and has
the ability to degrade RNA [20]. The amino acid
sequence of ECP has eight cysteine residues spaced all
throughout the peptide establishing the tertiary struc-
ture of the protein by the formation of four cysteine
double bonds. Two catalytic residues, a lysine and a his-
tidine, responsible for the RNA degradation have been
identified, K38 and H128 [20,21] (Figure 2) and these
residues together with the cysteines are present in all
members of the pancreatic ribonuclease family [20].
Analysis of the crystal structure of ECP verified this
relationship to these other members of RNase family;
namely a b-sheet backbone and three a-helices [22]. In
a grove between two of the alpha helices the catalytic
site for RNA degradation is located, with ECP showing
a preference for cleaving poly-U RNA but not double-
stranded RNA [23]. ECP consists of a single-chain pep-
tide of 133 a.a. containing three sites for N-linked glyco-
sylation, a.a.’s 57-59, 65-67 and 92-94 [24] (Figure 2).
The glycosylation is composed of sialic acid, galactose
A. Blood, negative control B. Blood positive, ECP
Figure 1 Identification of eosinophil granulocytes in peripheral blood by immunohistochemical detection of ECP. (A) Negative control
(omission of primary antibody). Shown are peripheral leukocytes after fixation, incubation with alkaline phosphatase-anti-alkaline phosphatase
(APAAP) with fast red substrate and counterstaining with Mayer’s hematoxylin. The characteristic red immune-labelling reaction is absent. (B)
Leukocytes are treated as in (A) but with addition of anti-ECP antibody. Peripheral leukocytes are visible but only the eosinophils have been
stained for ECP. Original Magnification (X420).
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agacccccacagtttacgagggctcagtggtttgccatccagcacatcagt
1   R  P  P  Q  F  T  R  A  Q  W  F  A  I  Q  H  I  S 
ctgaacccccctcgatgcaccattgcaatgcgggcaattaacaattatcga
18  L  N  P  P  R  C  T  I  A  M  R  A  I  N  N  Y  R 
tggcgttgcaaaaaccaaaatacttttcttcgtacaacttttgctaatgta
35  W  R  C  K  N  Q  N  T  F  L  R  T  T  F  A  N  V 
gttaatgtttgtggtaaccaaagtatacgctgccctcataacagaactctc
52  V  N  V  C  G  N  Q  S  I  R  C  P  H  N  R  T  L 
aacaattgtcatcggagtagattccgggtgcctttactccactgtgacctc
69  N  N  C  H  R  S  R  F  R  V  P  L  L  H  C  D  L 
c
ataaatccaggtgcacagaatatttcaaactgcaggtatgcagacagacca
86 I  N  P  G  A  Q  N  I  S  N  C  R  Y  A  D  R  P 
T
ggaaggaggttctatgtagttgcatgtgacaacagagatccacgggattct
103 G  R  R  F  Y  V  V  A  C  D  N  R  D  P  R  D  S 
ccacggtatcctgtggttccagttcacctggataccaccatctaa 
120 P  R  Y  P  V  V  P  V  H  L  D  T  T  I  * 
D1
D2
DE
E
E E
E
E
Figure 2 The RNASE3 (ECP) gene and ECP protein sequence with numbers referring to the amino acid sequence. Below the protein
sequence is a schematic diagram of the peptide sequence where the beta sheet domains and the alpha helix domains are shown as red arrow
and green barrel structures, respectively. Amino acids involved in RNase activity are represented by scissors. Amino acids involved in membrane
interference, heparin binding and bactericidal activity are represented by red arrows. Glycosylated amino acids are represented with a
glycomoiety while the letter N highlights the nitrated amino acid. A blue box shows the site of the amino acid altering polymorphism
rs2073342.
Bystrom et al. Respiratory Research 2011, 12:10
http://respiratory-research.com/content/12/1/10
Page 3 of 20
and acetylglucosamine [25] explaining the variation in
its detected size by Western blot of between 16 and 22
kDa [26]. Nineteen arginine residues facing the outside
of the protein giving rise to the proteins basicity (pI >
11) [27] and possibly also its extraordinary stability
compared to other ribonucleases [28]. In the presence
of H2O2 ECP can be nitrated on tyrosine Y33 by EPO.
This inflammation-independent nitration occurs during
granule maturation and was suggested to enhance inter-
actions after secretion between several of the otherwise
repulsive, positively charged granule proteins (Figure 2)
[29]. ECP has been shown to interact with artificial lipid
membranes [30] and two tryptophan residues, W10 and
W35 facing the outside, similar to the present arginine’s,
have been associated with this lipid membrane interac-
tion [31]. ECP also has RNase independent cytostatic
activity on tumour cells and the tryptophan residues
contribute to this activity [32]. W35 was additionally
found necessary for killing gram negative and gram
positive bacteria [31]. The tryptophan’s also facilitate
ECP binding to heparin [33,34]. Another study found
that the residues R34, W35, R36 and K38, all part of
loop 3 (a.a.’s 32-41) contributed to heparin binding and
cytotoxicity [35] (Figure 2). Surprisingly, when purified
from granules of circulating cells, large quantities of the
protein were found to lack cytotoxic activity [36]. ECP
has not, like EPX/EDN, been found have alarmin activ-
ity, stimulating dendritic cells during Th2 immune
responses [37], but ECP has the ability to bind lipopoly-
saccharide (LPS) and other bacteria cell wall compo-
nents [38] which might have a priming influence on the
immune system. The binding of LPS was mainly attribu-
ted to a.a.’s 1 to 45 [39]. The 1 to 45 a.a. region was
found to retain bactericidal activity as well as membrane
destabilization activity. One commonly occurring poly-
morphism in the gene is leading to the replacement of
an arginine residue with a threonine, R97T [40] (Figure
2). The a.a. alteration reduced ECP cytotoxicity to the
cell line NCI-H69 assessed by using both recombinant
protein [36] and pools of naive protein variants [41].
RNase activity was however not influenced by the R97T
alteration. Deglycosylation of the recombinant T97
restored the proteins cytotoxicity suggesting that glyco-
sylation are responsible for this inhibitory role.
The physiological function of the granule
contained cytotoxic ribonuclease
Eosinophils contain a large amount of ECP but the ques-
tion is why? What is the function of this protein? There is
a constitutive baseline level of the eosinophils in many tis-
sues and certain stimuli cause elevated production and
influx of eosinophils in different organs. Moreover levels
of the ECP in tissue and peripheral blood robustly corre-
lated with the number of eosinophils present, which might
be indicative that the function of ECP is also key to the
role of eosinophils (see table 1). Since the discovery of
ECP in 1977 [8] it has been used and evaluated as a bio-
marker to assess activity in various inflammatory diseases.
This analysis has given indirect information of the proteins
role in disease. For a comprehensive review of advantages
and pitfalls of the usage of ECP as a biomarker in allergic
disease see ref [42]. Furthermore, a number of in vitro stu-
dies have addressed the direct functional activities of the
protein. Detailed following is a comprehensive review of
these studies with summaries in table 1 and 2. To simplify
comparison the concentrations used have been recalcu-
lated to μg/mL using the mean Mw of 19.000 for the native
protein (average of 16-22 kDa).
ECP during homeostasis and measured in
inflammatory diseases
At homeostasis the eosinophil contributes 1 - 4 percent
of the circulating leukocyte pool. ECP is readily detect-
able in blood with plasma levels on the average 3 ug/L
(serum 7 μg/L) in healthy individuals which correlates
with circulating eosinophil numbers [43]. ECP in blood
shows a turnover time (t1/2) of 45 min [44], and the
plasma protein a2-macroglobulin (a2M) is found to be
associated to the protein, in vitro at a molar ratio of 1.6
(ECP/a2M). This interaction is facilitated by proteolytic
activity of cathepsin G or methylamine [45], and concei-
vably takes place to facilitate the clearance of ECP [46].
When eosinophils encounter adhesion molecules
expressed on the endothelial cells of post capillary
venule wall, the cells adhere and emigrate through the
cell layer [47]. Local signals do however drive a low
level influx of eosinophils in specific tissues at homeos-
tasis. Eosinophils are present in almost all mucosal asso-
ciated tissues, nasal mucosa [48] (Figure 3B), lungs [49]
(Figure 4B), gastrointestinal mucosa [50], the reproduc-
tive tract, the uterus [51], breast mucosa of mice [52]
and skin [53]. The chemokine eotaxin is responsible for
homeostatic eosinophil influx in the gastrointestinal
tract in mice [54] whereas the mechanism of influx in
other organs remains unknown. In addition, lympho-
cyte-associated tissue: lymph nodes [50], thymus [55]
and spleen [50] will have some cells stained red by eosin
(see Figure 5).
The majority of ECP is released after the cell has left
the circulation [56]. Several types of inflammatory sti-
mulation have been shown to cause eosinophil degranu-
lation. Interaction with adhesion molecules [57,58],
stimulation by leukotriene B4 (LTB4), platelet activating
factor (PAF) [59], interleukin (IL)-5 [60] immunoglobu-
lins and complement factors C5a and C3a [61] all cause
ECP release. Upon stimulation of eosinophils small var-
iants of ECP with sizes 16.1 and 16.3 kDa are released
[62]. One line of studies have suggested that during
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Table 1 ECP level in biological fluids and tissues
Biological Fluid ECP concentration (ng/mL) Eosinophils (×10 6)/mL
Plasma
Normal value 3.5 0.104 (±0.033) [112]
Ongoing asthma/allergy 3.5 N/A [43]
S. mansoni infection 27 0.4 (0.2-0.8) [156]
Reactive eosinophilia with a inflammation 75 1.9 (±3.2) [112]
HES 243 19.9 (±10.9) [112]
Serum
Normal value 7 N/A
Ongoing allergy/asthma 15 N/A [43]
S. mansoni infection ~62 0.163
Atopic Dermatitis inflammation ~50 0.315
Bacterial infection ~19 N/A [72]
HES 45- 198 22-58 percent of total cells [111]
Renal tumour ~30 N/A [123]
BALF
Normal value ~4 0.2 (±0.1)
Atopic asthma (challenged) ~40 55.0 (±34.3) [97]
Drug-induced ARDS 13.8 4 percent of total cells [78]
Sputum
Normal value 95 0.2 percent of total cells
Asthma 735 13.4 percent of total cells
Eosinophil bronchitis 604 12.4 percent of total cells [157]
Experimental Viral Day -5 119.1 (8.9-1,146) 9.3 (0-30.3) percent of total cells
Rhinovirus infection Day 2 190.6 (17.2-800) b) 7.5 (0.1-34.4) percent of total cells
Day 9 157.9(27.8-800) 5.5 (0.4-23.3) percent of total cells [136]
Nasal lavage
Normal value 3-31 N/A [158]
Allergic rhinitis 9 ± 2.4 19 (±2.1) percent of total cells
Allergic rhinitis 6 hr after allergen challenge 36.6 ± 12 56.7 (±5.8) percent of total cells [159]
Nasal secretions
Normal value 56.2 (33.5-94.2)
RSV infection 379 (269-532) [75]
Natural cold 13038
Severe community acquired bacterial sinusitis 117 704 [77]
Tears
Normal value <20 1 (±0.2) cells/mm2 in subepithelium [160]
Atopic keratoconjunctivitis 215 (36-1900) [161] N/A
Vernal keratoconjunctivitis 470 (19-6000) [161] 112 (±37) cells/mm2 in subepithelium [160]
Skin, cutaneous
Normal N/A
Atopic dermatitis >16 000 [64]
ECP measurements in various biological fluids. Type of fluid, concentration of ECP measured and number of eosinophils are presented.
a) Patients with asthma, atopic dermatitis, lung disease, GI diseases, idiopathic/autoimmune inflammatory conditions
b) Statistically significant increase
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Table 2 In vitro experiments analysing the activity of ECP
Cell type or other ECP added
(μg/mL)
Incubation
time
Outcome compared to control Inhibitory factors used Reference
Interactions with immune cells, epithelium and fibroblasts
human mononuclear cells
(lymphocytes) stim. by PHA
0.2-2 48 hr 67 - 50 percent inhibition of
growth
[86]
Plasma cell line 0.5 ng/mL inhibition of Ig production anti ECP ab [87]
B lymphocyte cell line 1 ng/mL inhibition of Ig production [88]
Rat Peritoneal Mast Cells 17 45 min 50 percent increased histamine
release
[92]
Human heart Mast cells 4.7 60 sec 10-80 percent increased histamine
release PGD2 synthesis
Ca 2+, temperature [94]
Guinea-pig tracheal epithelium 103 6 hr exfoliation of mucosal cells [79]
Feline tracheal epithelium 2.5 1 hr release of respiratory conjugates [99]
Human trachea 2.5 [99]
Human primary epithelial cells 10 6 hr rECP, necrosis [80]
Bovine mucus 100 3 fold altered structure [97]
Nasal epithelial cells 2.1 ng/mL upregulation of ICAM-1 [100]
Human corneal epithelial cells 100 decreased cell viability [98]
Epithelial cell line NCI-H292 20 ng/mL 16 hr upregulation of IGF-1 [102]
Human fetal lung fibroblast
(HFL1)
10 48 hr release of TGF beta, collagen
contraction
[81]
Human fetal lung fibroblast
(HFL1)
10 5 hr rECP and naive, migration anti ECPab [107]
Human fetal lung fibroblast
(HFL1)
10 6 hr 6 fold increased proteoglycan
accumulation
[108]
Potential effects due to high ECP levels in circulation and skin
Injection in skin intradermally 48 - 190 7 days ulceration, inflammatory cell influx poly lysine, MPO, onconase,
carboxymethylation of RNase site, RI
[114]
Plasma 18 Influencing coagulation factor XII,
shortened coagulation time
[117]
Myosin heavy chain (MHC) 16.25 8 hr 20 percent degradation of 50 ug
MHC
[118]
Guinea-pig intracerebrally 0.1-30 0 - 16 days low dose affecting cerebral activity,
high dose, death
[121]
Human cell lines
K562 21 4 days 50 percent inhibition of growth [34]
HL-60 21 4 days “ [34]
A431 76 4 days “ [34]
KS Y-1 1 16 hr 29 percent decreased viability [126]
HL-60 80 rECP, 50 percent inhibition of
growth
[31]
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inflammation whole eosinophil granules are released
from disrupted cells (Figure 4B) and that internal pro-
teins are subsequently released differentially through the
process of piece meal degranulation [4].
Several diseases are associated with eosinophils and
ECP. Most common are diseases associated with atopy
and the T helper lymphocyte type 2 (TH2) phenotype.
Cytokines such as IL-5 [63], or chemokines such as
eotaxin are produced in elevated levels and attract ele-
vated numbers of eosinophils to the lumen and bronchi
of the lungs in asthma [49] (Figure 4B), the nasal mucosa
in allergic rhinitis [48] (Figure 3B) and to the skin in ato-
pic dermatitis [64]. In addition, the gastrointestinal tract
and esophagus are infiltrated during conditions such as
ulcerative colitis [65] and eosinophil esophagitis [66].
ECP has been measured in disease and the increase in
number of activated eosinophils is associated with eleva-
tion of serum ECP (sECP) and plasma ECP levels [67].
Anticoagulants such as EDTA attenuate ECP release
from eosinophils giving a snapshot of the in situ ECP
level in plasma. sECP level on the other hand is often
higher than plasma ECP as it’s an artificial measure
obtained by detection of the protein released during the
blood clotting process in the test tube. sECP is thought
to reflect the activation state of eosinophils [68]. ECP has
also been detected in several other biological fluids such
as bronchoalveolar lavage fluid (BALF), sputum, nasal
lavage and in mucosa of the intestine [69]. ECP levels in
various biological fluids in various diseases are presented
in table 1. ECP measurements in allergic asthma have
been found useful in monitoring the disease as sputum
ECP correlates with forced expiratory flow (FEV) [70]
and the need for glucocorticosteroid (GC) therapy while
sECP correlate with eosinophil numbers in blood [71].
sECP is also elevated in some but not all cases of TH2
cytokine associated atopic dermatitis [72] eosinophil eso-
phagitis [73], parasite infection [74] and childhood
respiratory syncytial virus (RSV) infection [75]. Raised
levels of ECP have also been found in some cases that are
not TH2 associated; a group of patients with bacterial
infections had elevated sECP [76], very high levels were
found in nasal secretions from patients with bacterial
sinusitis [77] and in sputum of a patient with tuberculosis
and drug-induced acute respiratory distress syndrome
(ARDS) [78]. Malignancies with primary eosinophilia are
associated with the highest measurable sECP levels (see
HES and malignancy section). Polymorphisms have been
shown both to alter expression level and the function of
the protein which might complicate the usage of the pro-
tein as a biomarker (see polymorphism section). The
pathology attributed to eosinophils and ECP has been of
both acute character such as defoliation of airway epithe-
lium or activation of other cells [79-81] and of a chronic
type, such as fibrosis in lungs [49] (Figure 5). Below we
discuss the studies that indicate how ECP release influ-
ence other cell types locally (Figure 6).
ECP and lymphocytes
Lymphocyte activation mutually with ECP level has been
shown to correlate with acute exacerbations in asthma
Table 2 In vitro experiments analysing the activity of ECP (Continued)
HeLa 160 [31]
HeLa 320 72 h
1 hr
24 hr
50 percent inhibition of growth
4 fold increase in cytosolic Ca2+
1.5 fold increase in Caspase like
activity
[125]
Interaction with pathogens
Larvae of S. mansoni 190 60 percent killed [131]
Three day old S. mansoni 190 paralyzing [131]
Trypanosoma cruzi 950 6 hr 40 percent killed [132]
Brugia malayi 950 48 hr 90 percent killed [132]
Escherichia coli 50 2 hr 72 percent decreased cfu [135]
Staphylococcus aureus 50 2 hr 100 percent decreased cfu [135]
“ “ 16 o.n. rECP, 65 percent decreased cfu [21]
RSV-B 9.5 rECP, 6 fold reduction in infection [139]
ECP’s influence on human cells, parasites, helminths, bacteria and viruses analysed in vitro. Presented in the table are amount protein used, duration of exposure,
outcome and means to block the activity to prove specificity of the influence. anti ECPab: anti ECP antibody, rECP: recombinant ECP, RI: RNase inhibitor, o.n.: over
night, cfu: colony forming units
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[82]. sECP is also reduced during immune therapy
which is a regimen that suppresses lymphocyte activity
[83]. Eosinophils have been shown to migrate to lymph
nodes where they might interact with T- lymphocytes.
Eosinophils up-regulate major histocompatibility com-
plex class II [84] for antigen presentation, thereby possi-
bly contributing to T-lymphocyte activation and the
increased inflammatory response during allergic inflam-
mation [85]. Eosinophils are also present in the lympho-
cyte rich organs, the thymus and spleen and lamina
propria of the gastrointestinal (GI) tract [50]. Although
no studies have shown any direct link between ECP
release and lymphocyte function, ECP released during
the inflammatory processes, co-localises with lympho-
cytes. In vitro ECP has been shown to influence the pro-
liferation of T and B lymphocytes which indicate that
the protein could regulate those cells in vivo (Figure 6).
This was shown when mononuclear cells (containing
lymphocytes, 2 × 105) were incubated with or without
phytohaemagglutinin (PHA) and low levels of ECP (1
nM - 0.1 μM, 190 ng/mL-2 μg/mL) for 48 hr, resulting
in 50-67 percent inhibition of proliferation of the lym-
phocyte fraction [86]. The cells were not killed by these
low levels of ECP. B lymphocyte activity might also be
influenced by ECP since low levels (0.5-1 ng/mL) inhibit
immunoglobulin production by plasma cells [87] and by
B lymphocyte cell lines [88]. This effect was inhibited by
anti-ECP antibodies and ECP was not toxic to the cell
lines as cell proliferation was not inhibited with these
low concentrations. IL-6 could restore the immunoglo-
bulin production by the plasma cells and IL-4 had the
same influence on the B lymphocytes. Primary human
A. Healthy Control
B. Allergic rhinitis
Figure 3 Eosinophil granulocytes in the nasal mucosa. (A) Immunohistochemical staining of nasal biopsy specimens for ECP in (A) a healthy
control and (B, C) a patient with perennial allergic rhinitis. In healthy controls (A), a few cells are staining weakly for ECP in the submucosa and
epithelium. In patients with perennial allergic rhinitis cells staining intensely for ECP are present in the submucosa and epithelium. (original
magnification, ×420). (C) Higher magnification highlighting eosinophil granules in the epithelium residing cells (original magnification ×1050);
Mayer’s hematoxylin.
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plasma cells and large activated B lymphocytes
responded to ECP in a manner similar to that of the cell
lines [87]. Thus, ECP might influence the immune sys-
tem in that immature lymphocytes are inhibited in their
proliferation by ECP while activated B lymphocytes
respond by decreased immunoglobulin production (see
Figure 6).
ECP and Mast cells
Mast cells are found in the skin and in all mucosal tis-
sues at homeostasis, and numbers are elevated in asth-
matics lungs [49]. Mast cell and eosinophil numbers in
mucosa are correlated to bronchial hyperactivity (BHR)
[89] and mast cell products and eosinophil MBP but not
ECP induces BHR [90]. Several lines of evidence suggest
that there is a cross talk between eosinophils and mast
cells [91] which to some extent are related to ECP
release. Mast cells produce and secrete IL-5, PAF and
LTB4 known to augment ECP release from eosinophils.
Rat peritoneal mast cells on the other hand incubated
with moderate levels of ECP (0. 9 μM/17 μg/mL) for 45
min released 50 percent of their histamine. Histamine is
not released from peripheral basophils by ECP treatment
(as by MBP) [92]. However, the release of histamine
may be location specific as no release was observed
from human skin mast cells treated with up to 200 μg/
mL ECP [93]. Histamine and of some tryptase was
though released from human heart mast cells, purified
from traffic victims or from individuals undergoing
heart transplantation, when stimulated with moderate
levels of ECP (2.5 μM; 4.7 μg/mL). Between 10 and 80
percent of preformed mediators were released from
these cells and MBP had a similar effect whereas EPX/
EDN did not induce any release [94]. This ECP induced
histamine release occurred within 60 sec of stimulation
and was found to be Ca2+-, temperature- and energy
dependent, and ECP was not toxic to the cells. Another
mast cell product, prostaglandin D2 (PGD2) was synthe-
sised de novo by the same amount of ECP added. PGD2
is a chemoattractant for eosinophils and TH2 lympho-
cytes, through binding the CRTH2 receptor [95]. There-
fore these findings suggest that in some tissue the
interactions between mast cells and eosinophils can be
attributed to the positive feedback of ECP release.
ECP and epithelium
ECP is detected in nasal mucosa in association with
damaged epithelium [48], in damaged corneal epithe-
lium [96] as well as in BALF (at 40 ng/mL, table 1) [97].
The function of ECP has been assessed using several
assays in the view of the presence of the eosinophil in
the airways. Both destructive and non-destructive conse-
quences have been found when analyzing various con-
centrations of the protein in interaction with the
epithelium. High levels of ECP (5.4 μM/103 μg/mL)
caused exfoliation of guinea-pig mucosal cells after 6 hr
incubation with tracheal epithelium [79]. Confluent pri-
mary human corneal epithelial cells incubated with 0-
100 μg/mL ECP, displayed a concentration-dependent
gradual increase in morphological change and with the
highest concentration, 100 μg/mL, being cytotoxic [98].
Lower concentration of the ECP (2.5 μg/mL) caused
release of respiratory glycoconjugates (marker of mucus
secretion), with a peak after 1 hr, from feline tracheal
B. Allergic asthmaA. Healthy control
Figure 4 Eosinophil granulocytes in the bronchial mucosa. Sections of bronchial biopsies from (A) a healthy control or (B) an individual with
allergic asthma were stained with ECP antibody visualizing eosinophils in the mucosa. The figures show that only a few eosinophils are present
in the tissue of the healthy control, but many eosinophils accumulate in areas of reduced epithelial integrity in a specimen from a patient with
allergic asthma. Original magnification ×420; Mayer’s haematoxylin.
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explants [99]. The short incubation time and possibility
to repeat the stimulation suggested a non-toxic mechan-
ism. MBP, which is almost as basic as ECP, in the same
assay, showed the opposite effect; therefore these effects
on mucus secretion are unlikely to be due to electrostatic
charge. ECP at these moderate levels (2.5 μg/mL)
displayed the same effect on human trachea [99]. However
human primary epithelial cells underwent necrosis at
higher levels (10 μg/mL) in another study [80]. ECP has
also been shown to acting directly on airway mucus in
vitro. At high levels (100 μg/mL) ECP altered bovine
mucus three fold, as measured by a capillary surfactometer
Thymus
Location of
eosinophils 
at homeostasis
Lung
G.I. tract
Spleen
Reproductive
tract
Lymph nodes
Respiratory mucosa
Damaged epithelium (P)
Bacterial defence (F)
Bronchi
Epithelium – exfoliation (P)
Mucus - altered (P)
Suggested function (F) or 
pathology (P) of eosinophils
and released ECP
Heart
Scarring Fibrosis (P)
Lung
Tissue remodelling (P)
Fibrosis (P)
Viral defence (F)
Esophagus
Damaged epithelium (P)
Fibrosis (P)
GI tract
Helminth defence (F)
Bacterial defence (F)
Skin
Ulceration (P)
Figure 5 Known anatomical locations of eosinophil granulocytes and suggested activities of released ECP at these sites. On the left
side are eosinophil granulocytes locations at homeostasis shown. On the right side are areas speculated to be affected by increased numbers of
eosinophils and elevated levels of released ECP, in disease (pathology, P) and in physiological defense (function, F). This is a speculation by the
authors of the review.
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[97]. At low levels ECP (0.1 nM; 2.1 ng/mL) was instead
found to increase the expression of intracellular adhesion
molecule (ICAM)-1 on nasal epithelial cells [100]. ECP
has previously been shown to be released from eosinophils
when the cells adhere with their b2 (CD18) integrins to
ICAM-1. Therefore the ECP triggered up-regulation of
ICAM-1 on epithelial cells might mediate a positive feed-
back mechanism [101]. ECP has also been proposed as a
mediator of tissue remodelling, see the fibroblast section
below. When low levels of the protein (20 ng/mL) were
Mast cell
Fibroblast
Epithelium
T-cell B-cell, plasma cell
Cancer cells
Growth inhibition
Decreased viability
TGF β release
proteoglycan accumulation
migration
Low: Upregulation of ICAM1
Low: Upregation of IGF-1 receptor
High: Exfoliation
Growth 
inhibition Inhibition of
Ig production
Histamine release
PGD2 synthesis
ECP
ECP
E.coli
S.aureus
Helminths
Parasites
Respiratory syncytial virus
Decreased cfu
Growth inhibition
Death, paralysis
Decreased
infectivity
Figure 6 ECP’s specific influences on various cell types and micro organisms in vitro. Alpha helixes in the protein are shown with green
color and the location of the active site is marked with a red dot. Open arrow indicates moderate (1-5 μg/mL) to high (>5 μg/mL)
concentrations of ECP used in the in vitro experiments. Filled arrow indicates low amounts of ECP used in the in vitro experiments (<1 μg/mL).
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used to stimulate the bronchial epithelial cell line NCI-
H292 for 16 hr, the insulin growth factor (IGF)-1 receptor
was found to be up-regulated [102]. ECP was speculated
therefore to be involved in IGF-1-dependent lung tissue
repair processes perhaps present during homeostasis and
abnormally amplified during inflammatory conditions.
ECP and Fibroblasts
The persistent high number of eosinophils and ECP in
the lungs of allergic asthmatics has led to the suggestion
of their participation in the development of chronic
lung tissue remodelling. Remodelling has also been
found in the esophagus of patients with eosinophil eso-
phagitis [103] and sECP has been found elevated in one
case [104]. The remodelling in asthmatic lungs is in part
caused by collagen and proteoglycan secretion from
interstitial fibroblasts. Eosinophils have been suggested
to participate in this by secretion of transforming
growth factor (TGF) beta [105,106] but here is addition-
ally described how ECP could influences fibrosis devel-
opment. Stimulation of a human fetal lung fibroblast
cell line (HFL1) with moderate/high levels of ECP (5-10
μg/mL) for 24-48 hr resulted in increased release of
TGF-beta [81]. ECP also augmented fibroblast mediated
contraction of collagen gel and stimulated migration of
HFL1 fibroblasts which could be blocked with antibo-
dies to ECP [107]. In addition, ECP incubated with the
fibroblast cell line for 6 hr resulted in a 6-fold increase
of intracellular proteoglycan accumulation [108].
ECP and bronchial smooth muscle cells
Bronchial smooth muscles cells are involved during the
progression of asthma development by secretion of cyto-
kines as well as remodelling due to proliferation. Eosino-
phils have been found located in close proximity with
smooth muscle cells. ECP does not influence smooth
muscle cells by causing BHR [90] but high levels of
ECP, similar to used for epithelial cells, appears to be
cytotoxic, inducing cell death by necrosis in 1 hr. TNF
alpha in contrast causes apoptosis of the smooth muscle
cells [109].
ECP in Hypereosinophilic Syndrome (HES)
Conditions where eosinophils are overproduced lead to
detrimental effects for the host. One such condition,
HES is defined by the presence of more than 1.5 × 106
eosinophils/mL blood during a time period of at least 6
months, organ involvement and with no other etiology
identified. One form of HES, the myeloproliferative
form, is caused by an 800 bp deletion on chromosome 4
during the haematopoiesis in the bone marrow, resulting
in a fusion between the gene FIP1L1 and the PDGFRA
gene [110]. A fusion protein is produced which constitu-
tively phosphorylates tyrosine residues leading to
malignant expansion of eosinophils. Another form of
HES is a clonal lymphocytic variant (L-HES) where
aberrant cytokine production by malignant lymphocytes
causes HES. For other cases the cause of the overpro-
duction of the eosinophils is unknown but HES is asso-
ciated with high levels of ECP in plasma and serum, of
up to 0.2 μg/mL [111,112]. It is not know however
whether theses high levels of the protein are pathologi-
cal. A few in vitro studies might relate to the etiologies
of HES. Eosinophil infiltration of the skin of HES
patients is the most common clinical manifestation
[113]. Some of these patients present with erosive and
ulcerative lesions and ECP was found both deposited
and taken up by cells in those lesions [114]. ECP’s abil-
ity to cause ulcerations in the skin has been analysed by
injecting the protein intradermally into guinea pig skin,
where it was found that the protein can persist there for
two weeks [64] which is possibly attributed to its high
stability [28]. Injections of high levels of ECP (48 and
190 μg/mL/2.5 and 10 μM) caused ulcerations which
were most severe after seven days [114]. Inflammatory
cells were found infiltrating the inflamed area and ECP
was found taken up by cells within 48 hr. Injection of
poly-lysine, other basic granule proteins MBP, EPO and
the basic ribonuclease onconase showed that the severity
of the lesions was not directly correlated with level of
basicity. ECP and EDN were found to be more potent in
lesion formations than MBP and EPO. Addition of
RNase inhibitor or obliteration of the RNase activity by
carboxymethylation of the RNase site of ECP reduced
the ulcerations by 60 percent suggesting RNase activity
is important, but not wholly responsible for the activity
[114]. Some studies have shown that patients with HES
have an slightly elevated risk for thrombosis formation
systemically [115] and in the cardiac ventricle [116].
ECP has been shown to shortened the coagulation time
for plasma which was dependent on an interaction with
coagulation factor XII [117]. Eosinophils also infiltrate
the endomyocardium of some patients and this has been
suggested to be the cause of development of scaring in
the ventricle [116]. High levels of ECP (16.25 μg/mL)
degrade the muscle protein component, the myosin
heavy chain in vitro [118] but it is not known whether
ECP directly interacts with muscle fibres of the heart.
The final stage is endomyocardial fibrosis in which eosi-
nophils and ECP have been postulated to participate
[119] by their influence on fibroblast function. Although
a rare finding, a few patients with the myeloid form of
HES have been reported to have central nervous system
(CNS) manifestation [113,120]. It is not known whether
ECP can reach the brain but ECPs effect on the CNS
has been assayed by direct intracerebral injection. Gui-
nea-pigs injected with ECP, showed with doses of 0.1 μg
and up, cerebral symptoms up until the end of the
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experiment at day 16 [121]. Purkinje cells in the brain
were decimated in this model, suggesting that the circu-
lating ECP could affect the CNS of some HES patients if
the protein reached the brain.
ECP in malignancies
Eosinophils have occasionally been found to infiltrate
developing tumours and have been suggested to have a
role in fighting these malignancies [122]. The involve-
ment of the eosinophils have been suggested by the
finding of elevated sECP levels in patients with renal
tumours (table 1) [123]. ECP assayed in urine from
patients with urinary bladder tumours showed a twofold
increase compared to normal’s [124]. The elevated levels
suggest presence of activated eosinophils in some
patients with these malignancies. In the analysis of the
possible involvement of ECP in tumour defence, ECP
has been evaluated in respect of altering proliferation of
various cell lines. The cell lines K562 and HL-60 were
incubated with 1.1 uM (21 ug/mL) ECP and the cell line
A431 with 4 μM (76 ug/mL) and this resulted in 50 per-
cent inhibition of proliferation after four days. To ana-
lyse whether growth inhibition was related to positive
charge or RNase activity, poly-lysine or RNase A was
used with no effect [34]. ECP exists in two forms depen-
dent on a polymorphism, R97 and T97. It was found
that the T97 form had reduced capability to kill K562
and NCI-H69 cells [36]. These recombinant (r) ECPs
were produced in a baculovirus system and deglycosyla-
tion restored the cytotoxic activity.
Furthermore, high levels of bacteria expressed rECP
had 50 percent cytostatic effect on HL-60 and HeLa
cells [31], compared to non-affected controls. ECP was
found binding the surface of HeLa cells and caused cell
death after 24 hr, accompanied by increases in intracel-
lular radical oxygen species (ROS) generation and cas-
pase 3-like activity [125]. A mix of ECP and EDN
purified from urine and incubated with the Kaposi’s sar-
coma cell line KS Y-1 for 16 hr caused complete cell
death at 0.625 μg/mL while 1 μg recombinant ECP pro-
duced in yeast and incubated with the same time span
decreased the viability of the KS cell line by 29 percent.
Proteins expressed in yeast lack glycosylation and the
possible implications of this were speculated [126].
ECP as a defence protein
Levels of serum ECP are elevated in TH2 engaging para-
sitic and helminth infections and eosinophils have long
been thought to be a major defence against these types of
infection. Elevated ECP have also been reported in some
cases of bacterial and viral respiratory infections. Given
that ECP is a cytotoxic ribonuclease, the ability of the
protein to exterminate parasites, bacteria and virus in
vitro has been extensively investigated (see also Figure 6).
Parasite and helminth infections
Parasitic and helminthic infections drive the immune sys-
tem towards TH2 cytokine production and concurrent
eosinophilia. Since eosinophil infiltration in infected
organs and skin is a common finding, eosinophils are
thought to have a specific role in parasite killing [127].
Although, a challenged theory; the deposition of the cyto-
toxic protein ECP could be a mechanism by which the
immune system kills off the intruders. Indeed, the eosi-
nophilia in parasitic diseases is associated with elevated
ECP in circulation (table 1) [72,128]. ECP is also found
released from eosinophils in proximity to parasites in
skin and lymph nodes [129,130]. The ability for ECP to
kill or paralyse parasites and helminths have been ana-
lysed in vitro and high quantities were needed to influ-
ence the organisms. Three-hr-old larvae of Schistosoma
mansoni were incubated with 10 μM (190 μg/mL) ECP
and 60 percent were killed. S. mansoni, 3 days of age,
were paralysed by the protein [131] while 50 μM (950
μg/mL) ECP killed 40 percent of Trypanosoma cruzi by 6
hr and 90 percent of Brugia malayi by 48 hr. This cyto-
toxicity of ECP to parasites was inhibited by heparin
[132] and dextran sulphate, probably by interfering with
the tryptophan and arginine residues as discussed earlier.
In addition, heat obliterated the toxic effect of ECP to
parasites, highlighting the importance of the conforma-
tion of the protein [133]. The RNase activity of ECP was
clearly shown not to be important for parasite toxicity,
similar to that observed for EPX/EDN.
ECP in bacterial inflammation
Eosinophils are found lining and degranulating in both the
respiratory and gastrointestinal mucosa [50]. Eosinophils
are generally not thought of as defendants during bacterial
inflammation. However sECP has been found elevated in
septic patients [76] and very high levels of ECP in nasal
secretions from patients with normal cold (13 μg/mL) or
severe community acquired rhinosinusitis has been
described in one case (11.7 μg/mL, table 1) [77]. More-
over, a recent study has shown that eosinophils expel
mitochondrial DNA coated with ECP and other granule
proteins which are bactericidal in mice in vivo [134]. Addi-
tionally, a few studies have described neutrophils produ-
cing ECP [15]. In view of these findings the anti - bacterial
properties of ECP has been evaluated. Bacterial strains
chosen for analysis were Escherichia coli (E. coli) and Sta-
phylococcus aureus (S. aureus). High levels of ECP (50 μg/
mL) decreased the number of colony-forming units (cfu)
by 72 percent and close to 100 percent, respectively, for
the two strains after a very short 2 hr of incubation. ECP
only killed E. coli growing in logarithmic phase and acted
on both the inner and outer membranes of E. coli [135].
Recombinant ECP was also cytotoxicity to S. aureus. Over-
night incubation of rECP with the bacteria (16 kDa, 16 ug/
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mL/1 uM) left 35 percent of the cfu. rECP in which a.a.’s
involved in RNase activity had been substituted (K38R and
H128D), terminating the RNase activity, had no effect on
the bacterial killing activity [21]. In conclusion therefore,
eosinophils and ECP might have a role in bacterial
defence. Due to its stability, it might be feasible to specu-
late that ECP over time accumulate in mucus fluids such
as nasal secretions and act as a first line of defence against
bacterial intrusion.
ECP in viral inflammation
ECP has been found significantly elevated in sputum
from atopic subjects subjected to experimental rhino-
virus infection [136] and in nasal secretions from atopic
infants with respiratory RSV infection (table 1) [75].
Eosinophils and ECP are associated with RSV infection
in children’s lungs [137] and RSV can infect, and repli-
cate in eosinophils [138]. Recombinant ECP expressed
in a baculovirus system was used to evaluate whether
ECP can inactivate the B subtype of RSV. ECP (0.5 μM;
9.5 μg/mL) incubated with the virus showed a 6-fold
reduction of the infectivity of the virus to a human pul-
monary epithelial cell line [139]. This antiviral activity
was lower than that found with EPX/EDN (54-fold
reduction) [140], but the infectivity was increased by
addition of RNase inhibitor (RI) to both proteins during
incubation. Mixing the two proteins did not mediate
any synergistic effects on antiviral activity. RNase A,
however [up to 4 mM (76 mg/mL)], did not exert anti-
viral activity, suggesting that the RNase site but not
activity is important for inhibition of infectivity.
Polymorphisms in the RNASE3 gene and
association to production and disease
Table 3 summarizes data from the NCBI entrez nucleo-
tide site regarding polymorphisms detected in the ECP
gene. Two polymorphisms are found in the protein cod-
ing region, two in intronic regions and two in the 3’
untranslated region (UTR). ECP polymorphisms are dif-
ferentially distributed according to ethnicity [141]. Two
studies have evaluated polymorphisms in intronic and
UTR regions of the ECP gene, and linked them with
ECP production. One polymorphism rs11575981 (-393T
> C) located in the promoter, in an C/EBP binding site
was associated with decreased ECP level in serum, and
decreased binding of C/EBP alpha [142]. Another poly-
morphism, in the 3’UTR, rs2233860 (499G > C or 562G
> C) was associated with content of ECP in the eosino-
phils [143]. Three studies have analysed whether any
polymorphisms are linked to allergic asthma and allergic
rhinitis. The presence of the C allele in the nonsynon-
ymous rs2073342G/C (371G > C/434G > C) polymorph-
ism in the ECP gene, causing a.a. alteration Y97T, was
found to be associated with absence of asthma in one
Swedish study [40]. A study of Norwegian and Dutch
subjects instead found that the haplotype C-G-G for the
three polymorphisms rs2233859/rs17792481 (-38C/A),
rs2073342 (371G/C/434G/C) and rs2233860 (499G/C/
562G/C) being protective [144]. In a third, Korean
study, which was the largest, the genotype rs2233860CC
(499/562CC) was associated with allergic rhinitis [145].
Eosinophils occasionally infiltrate oral squamous cell
carcinoma tumours. A study found a tendency for asso-
ciation of the rs2073342G/C C/C (371/434GC/CC) gen-
otypes with a poor clinical outcome in patients with
eosinophil rich such tumours [146]. As discussed earlier,
eosinophils are present during helminth infections. The
rs8019343 polymorphism T (1088TT) in the 3’UTR was
exclusively present in the genome of a patient with tro-
pical pulmonary eosinophilia [147]. Furthermore a study
has found the rs2073342 with C (371/434C) polymorph-
ism overrepresented in helminth infected Ugandans
Table 3 Polymorphisms associated with the RNASE3 gene
Polymorphism alleles Alternative
names
location, effect
rs2284954 A/G -550A > G promoter
rs11575981 C/T -393T > C promoter, disrupt C/EBP binding site, correlate with s-ECP [142]
rs2233858 C/T intron
rs2233859/
rs17792481
A/C -38C > A intron (in a GATA-1 site) a
rs2073342 C/G 371G > C,
434G > C
protein coding, Y > G is associated with allergic asthma [40]a, poor outcome in oral squamous cell
carcinoma tumours [146], C over represented in helminth infected Ugandans [148]
rs12147890 A/G protein coding
rs2233860 G/C 3’ UTR,G is correlated to higher intracellular ECP [143], G is associated with allergic rhinitis [145], a
rs8019343 A/T 499G > C,
562G > C
3’ UTR T is only present in one patient with helminth infection [147]
Polymorphisms found in the ECP gene and surrounding chromosomal sequence. Listed are Polymorphism i.d.’s, altered bases, alternative names, and types of
associations
a) C-G-G haplotype associated with allergic rhinitis [144]
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[148]. Interestingly, from the -550 polymorphism over a
stretch of 272 bases to the mRNA transcription start
site, thirteen polymorphism sites are located (NCBI
Reference Sequence: NC_000014.7, J. Bystrom unpub-
lished observation). Similar to the protein coding region
and the 3’UTR, this region is highly homologous to the
RNASE2 gene region, with the only differences being
the sites of the polymorphisms. The replacement base’s
for twelve of the thirteen polymorphisms is to the same
base as in the RNASE2 promoter sequence. This is also
the case for two of the 3’UTR polymorphisms. This
further highlights the extremely close relationship
between RNASE3 (ECP) and RNASE2 (EPX/EDN).
Discussion
ECP was first discovered in 1977 and since then, evi-
dence has been gathered to understand its roles in phy-
siology and pathophysiology. ECP is a peptide of 133 a.
a., with the first 40 a.a. necessary for membrane interfer-
ing, heparin binding and cytotoxic activity. The heparin
binding ability of ECP might enable the protein to bind
proteoglycans on other human cells for possible uptake
[34] or heparan sulfate in extracellular matrix for later
use such as is the case for CXCL10 [149]. In a similar
manner ECP might bind microorganisms peptidoglycans
for uptake and cytotoxicity [32]. The non-synonymous
polymorphism rs2073342 reduces cytotoxicity suggesting
an alteration of the three-dimensional structure influen-
cing catalytic site elsewhere in the protein. ECP is glyco-
sylated, and as recently discovered can be nitrated. The
development of increasingly sophisticated assays will
determine whether other modifications, perhaps func-
tion associated, are also important in ECP activity.
Since the discovery of ECP, assays have been devel-
oped to determine its levels in biological fluids in var-
ious diseases (table 1). ECP in serum can reach 0.1 - 0.2
μg/mL for HES patients [111] and parasitic diseases
infected individuals [72] and this is a 30 fold elevation
compared to ECP in serum of healthy individuals. In
BALF and nasal lavage from atopic patients the ECP
levels are lower, 0.050 μg/mL but the sample are diluted
during the collection process. In undiluted tears, sputum
and nasal secretions the highest ECP levels have been
found: 0.5, 0.7 and 10 μg/mL, respectively. The ECP
measurements correlate with eosinophilic disease but
have been found elevated also in some diseases without
known eosinophil involvement [76-78]. The biological
activity of ECP has been studied by incubation of the
protein with several different cell types in vitro. Both
human cells and pathogens have been assayed analysing
different parameters (see table 2). In general, 10 - 20
μg/mL and above, result in growth inhibitory and
destructive consequences to mammalian cells, parasites
and bacteria. ECP released in situ in diseases engaging
high levels of eosinophils might reach these destructive
concentrations (e.g. ECP accumulated in air way mucus
of asthmatics, in nasal secretions of some sinusitis
patients or released in skin of atopic dermatitis/HES
patients, table 1 and Figure 5). Although it remains to
be proven, there is a possibility that destructive activity
to multiple cell types as well as induction of fibrosis is
part of the etiology of disease where ECP levels are ele-
vated during prolonged periods, e.g. in HES and hel-
minth infection. There is also evidence that neutrophils
are carriers of significant amounts of ECP. Using the
murine system, granule proteins have been found asso-
ciated with expelled eosinophil mitochondrial DNA and
this DNA/protein complex trapping and killing bacteria
in the gut [134]. It is intriguing to speculate whether the
high levels of ECP present in various human mucosal
secretions would equally be associated with eosinophil
mitochondrial DNA and whether such complexes had
the ability to capture and kill microorganisms.
The role of eosinophils in asthma has been under
scrutiny since clinical trials showing that anti-IL-5 ther-
apy did not improve the disease symptoms for allergic
asthmatics albeit eosinophil numbers were reduced
[150]. However, two recent clinical trials have shown
that anti-IL-5 antibodies actually could relieve symp-
toms in eosinophil rich, late onset asthma, suggesting
that eosinophils can have a pathogenic role in this dis-
ease. In these trials inflammatory exacerbations were
reduced when anti-IL-5 antibodies were administrated
[151,152]. Earlier studies using diagnostic ECP measure-
ments seem to agree with these findings as ECP levels
correlate with severity of asthma: FEV (sputum ECP)
[70], need for GC treatment (sputum ECP) [153] and
blood eosinophilia (sECP) [71]. Results from in vitro stu-
dies presented in this review may well suggest several
roles for ECP in this type of allergic asthma. The protein
might act as an inflammatory amplifier by augmentation
of release of, for eosinophils chemotactic, PGD2 from
mast cells in asthmatic patients. Moreover, protein
released in the interstitium might influence fibrosis
development (Figure 3B, 4B and 5). One might speculate
that blocking antibodies to ECP could be a symptom
relieving addition to the already established GC and
anti-IL5 therapies used in eosinophil rich asthma and
other eosinophilic diseases [113,151,152].
Table 2 shows that the level of protein needed to
influence proliferation of lymphocytes and their anti-
body production is 1000 times lower than the destruc-
tive levels described above, i.e. in the ng/mL range. In
murine system eosinophils have been ascribed a novel
role in inflammation; the cells enter and contribute to
the well orchestrated process of inflammation resolution
of by release of the pro-resolving lipid protectin D1
[154] (for a review see [155]). Whether ECP is released
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during this resolution process for the dual role of
sequestering subpopulations of inflammatory lympho-
cytes [86] and promoting tissue repair by TGF beta aug-
mentation [81] is an intriguing speculation. Eosinophils
are also present at homeostasis at low numbers in lym-
phocyte rich organs at various locations but degranu-
lated only in the GI tract [50]. A single eosinophil
contains 13 pg ECP. Do eosinophils have a role in main-
taining homeostasis and do low levels of ECP also have
a role here? EDN, the sister protein has been found to
play an active role during inflammation development
influencing the maturation of DC’s [37]. If EDN is pro-
inflammatory, perhaps the two proteins divergence
could be because ECP might have acquired a novel role
as yet unknown role.
Finally, analysis of the DNA sequence of the ECP gene
and surrounding regions have unravelled a number of
polymorphisms. These studies have linked different
polymorphisms and haplotypes to TH2 diseases, asthma,
and allergic rhinitis. The studies have in some cases
come to different conclusions but used different patients
and different ethnic groups which might explain the var-
iations. Diseases such as allergic asthma are multifac-
toral and to determine the role of certain
polymorphisms one might need to look at larger defined
groups to get a clear association. Altered expression
levels might also influence both destructive functions
and possible homeostatic roles. A careful analysis using
all polymorphisms and corresponding haplotypes and
large groups of defined populations would more clearly
determine the role of ECPs genetic make-up, and its
potential functions in physiology and disease.
Conclusion
The eosinophil granulocyte was discovered 130 years
ago but its roles are still being revealed. The most char-
acteristic feature of the eosinophil is the large secondary
granules filled with basic proteins. The purpose of these
proteins is still not fully understood. One of the pro-
teins, ECP is a highly basic, cytotoxic, heparin binding
ribonuclease that seems to need its ribonuclease site but
not activity for its activities. Sensitive assays have been
developed for its measurement in biological fluids which
have contributed to the understanding of the role of the
eosinophils in disease. In vitro studies have shown that
high levels of ECP are necessary for development its
destructive actions. Diseases engaging high levels of
eosinophils might reach these levels locally in the tissue.
At those high levels polymorphisms altering expression
level and protein sequence might play a role within cer-
tain populations. Whether ECP also has roles at lower
concentrations, such as the growth inhibitory influences
on lymphocytes found in vitro, remain to be shown with
in vivo models or clinically. These additional roles for
ECP when discovered, might provide critical answers to
the functions of eosinophil granulocytes and is therefore
well worth waiting for.
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